首页> 外文期刊>International Journal of Pharmaceutics >Release profile comparison and stability of diltiazem-resin microcapsules in sustained release suspensions.
【24h】

Release profile comparison and stability of diltiazem-resin microcapsules in sustained release suspensions.

机译:地尔硫卓树脂微胶囊在缓释混悬液中的释放曲线比较和稳定性。

获取原文
获取原文并翻译 | 示例
           

摘要

A sustained release suspension of diltiazem, a short half-life calcium channel blocker, was developed to reduce frequency of drug administration, ease of dose adjustment and improve patient compliance. In this study, the sustained release of diltiazem was obtained by complexing the drug with Dowex 50W x 4 and Dowex 50W x 8, strong cationic exchange resins with 4% and 8% degree of cross-linking, respectively. The diltiazem-Dowex 50W x 4 complexes provided the highest drug release and were subsequently used to prepare the microcapsules by emulsion-solvent evaporation method, using 0.75-5.00% cellulose acetate butyrate (CAB) in methylene chloride as a coating solution. As the concentration of CAB increased, the size of microcapsule increased and the drug release from the microcapsule was retarded. From release profile comparison using f(1) and f(2) factors, it was found that the microcapsules coated with 1.75% CAB provided a release profile equivalent to the commercial product of diltiazem sustained release capsule, Herbesser 90SR. Furthermore, sustained release suspensions of the diltiazem microcapsules were formulated with the use of 0.8% sodium carboxymethylcellulose or 0.4% xanthan gum as a suspending agent. The suspension of 0.4% xanthan gum showed superior in physical appearance after 120-day storage at 30 and 45 degrees C. In addition, all sustained release suspensions possessed good stability with low drug leaching and their release profiles were unchanged when compared with the dried microcapsules for 120 days at 30 and 45 degrees C.
机译:开发了地尔硫卓(一种半衰期短的钙通道阻滞剂)的缓释混悬剂,以减少给药频率,简化剂量调整并提高患者依从性。在这项研究中,地尔硫卓的持续释放是通过将药物与Dowex 50W x 4和Dowex 50W x 8分别与交联度为4%和8%的强阳离子交换树脂复合而获得的。地尔硫卓-Dowex 50W x 4复合物提供了最高的药物释放,随后被用于通过乳液-溶剂蒸发法制备微囊,使用的是0.75-5.00%的乙酸丁酸纤维素丁酯(CAB)的二氯甲烷溶液作为包衣溶液。随着CAB浓度的增加,微胶囊的尺寸增加并且药物从微胶囊的释放被延迟。通过使用f(1)和f(2)因子进行的释放曲线比较,发现包被有1.75%CAB的微胶囊的释放曲线与地尔硫卓缓释胶囊的商业产品Herbesser 90SR相当。此外,地尔硫卓微胶囊的缓释悬浮液是用0.8%羧甲基纤维素钠或0.4%黄原胶作为悬浮剂配制的。 0.4%黄原胶的悬浮液在30和45摄氏度下储存120天后表现出优异的物理外观。此外,所有缓释悬浮液均具有良好的稳定性,且药物浸出率低,与干燥的微胶囊相比,其释放特性没有变化在30和45摄氏度下放置120天。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号